Nucleic acid biomarkers for placental dysfunction
AssigneesSera Prognostics, Inc., The Regents of the University of California
InventorsJohn Jay Boniface, Julja Burchard, Ryan Michael Treacy, Louise C. Laurent
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for determining a pregnant female's risk of developing placental dysfunction later in the pregnancy.
Claims21
A panel of isolated nucleic acid biomarkers comprising two or more of the nucleic acid biomarkers listed in Tables 3-11 or 15-18.
(canceled)
-8. (canceled)
-13. (canceled)
A composition of labeled and/or amplified nucleic acid molecules, wherein said labeled and/or amplified nucleic acid molecules correspond to two or more of the nucleic acid biomarkers set forth in Tables 3-11 or 15-18.
(canceled)
-21. (canceled)
-26. (canceled)
A method for determining a pregnant female's risk of developing placental dysfunction later in the pregnancy comprising:
- (a) measuring the amount of two or more of the nucleic acid biomarkers listed in Tables 3-11 or 15-18 in a biological sample obtained from the pregnant female, calculating a risk score based upon the measured amounts of the nucleic acid biomarkers to determine the pregnant female's risk of developing placental dysfunction, and providing a score corresponding to the pregnant female's risk of developing placental dysfunction. or
- (b) comprising producing labeled and/or amplified nucleic acid molecules that correspond to two or more of the nucleic acid biomarkers set forth in Tables 3-11 or 15-18 in a biological sample obtained from the pregnant female;
- measuring the levels of expression of the labeled and/or amplified nucleic acid molecules;
- calculating a risk score based upon the measured levels of the labeled and/or amplified nucleic acid molecules to determine the pregnant female's risk of developing placental dysfunction.
-30. (canceled)
32 -35. (canceled)
-50. (canceled)
Dependencies are inferred from the claim text.